Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Clinical trial NCT01427946 · COMPLETED
Trial details
- NCT number
- NCT01427946
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-07-01
- Primary completion
- 2014-06-01
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.